Plasminogen Activator Inhibitor-1 Level Correlates with Lipoprotein Subfractions in Obese Nondiabetic Subjects

Table 1

Anthropometric and routine laboratory parameters of the study participants.

	Obese ()	Control ()
Gender (F/M)	43/7	27/5	ns
Age (yr)	44.20 ± 13.50	41.78 ± 5.97	ns
Body mass index (kg/m^2)	41.96 ± 8.63	24.47 ± 2.51	<0.001
Waist circumference (cm)	119.76 ± 16.87	83.62 ± 9.25	<0.001
hsCRP (mg/l)	8.24 (3.2–13.09)	1.57 (0.6–2.94)	<0.001
Fructosamine (μmol/l)	225.32 ± 27.95	229.0 ± 11.65	ns
Thyroid stimulating hormone (mU/l)	1.98 ± 0.98	1.93 ± 1.15	ns
Lipid parameters
Triglyceride (mmol/l)	1.4 (1.1–2.0)	1.0 (0.75–1.39)	<0.01
Total cholesterol (mmol/l)	5.04 ± 0.83	5.07 ± 0.78	ns
HDL cholesterol (mmol/l)	1.36 ± 0.33	1.56 ± 0.46	<0.05
LDL cholesterol (mmol/l)	3.17 ± 0.74	2.93 ± 0.52	ns
Apolipoprotein A–I (g/l)	1.48 ± 0.24	1.68 ± 0.31	<0.01
Apolipoprotein B (g/l)	0.86 ± 0.20	0.94 ± 0.18	ns
Lipoprotein(a) (mg/l)	248 (120–586)	70 (30–214)	<0.001
Carbohydrate parameters
Hemoglobin A1C (%)	5.76 ± 0.54	5.07 ± 0.33	<0.001
Fasting glucose (mmol/l)	4.90 ± 0.75	4.82 ± 0.48	ns
OGTT 120 min	7.00 ± 2.01
Fasting insulin (mU/l)	21.01 ± 15.91
HOMA-IR	3.75 (2.4–6.52)
Inflammatory and oxidative markers
Tumor necrosis factor-α (pg/ml)	1.783 (1.41–2.254)	1.39 (1.20–1.67)	<0.01
Interleukin-6 (pg/ml)	3.439 (1.817–4.89)	0.97 (0.63–1.28)	<0.001
Oxidized LDL (U/l)	46.8 ± 9.95	41.1 ± 9.57	<0.01
Paraoxonase activity (U/l)	64.72 (43.79–149.52)	83.03 (47.9–167.4)	ns
Arylesterase activity (U/l)	121.61 ± 23.65	131.1 ± 28.75	ns
Myeloperoxidase (ng/ml)	280 (148.3–386.3)	207.9 (125.8–265.2)	<0.05

Values are presented as deviation or median (lower quartile–upper quartile). HDL: high-density lipoprotein; hsCRP: high-sensitivity C-reactive protein; LDL: low-density-lipoprotein; OGTT: oral glucose tolerance test; HOMA-IR: homeostasis model assessment-insulin resistance; ns: nonsignificant.